Quest Diagnostics Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B). The key difference: Quest Diagnostics Inc and Vanguard International High Dividend Yield ETF are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| DGX | VYMI | |
|---|---|---|
Market Cap | $25.48B | $22.80B |
Volume | 941,866 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $107.13 |
52-Week Low | $173.49 | $82.92 |
Typical Hold Time | 56 Days | 50 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
VYMI trades at $100.06, down 0.17% with bearish technical signals from moving averages. The ETF shows strong institutional interest with recent stake increases from Envestnet and Corient Private Wealth. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with lower fees. The fund's heavy financial sector exposure (43.6%) benefits from rising global interest rates.
VYMI presents a compelling international dividend growth opportunity with attractive valuation and income characteristics. Key risks include concentration in financials and sensitivity to global economic conditions. The ETF's low 0.07% expense ratio and strong historical performance support its appeal for income-focused investors seeking international diversification.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →